1-3 of 3
Hampartsoum B. Barsoumian
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti–PD-1 in Metastatic Non–Small Cell Lung Cancer

Kewen He, Hampartsoum B. Barsoumian, Nahum Puebla-Osorio, Yun Hu, Duygu Sezen, Mark D. Wasley, Genevieve Bertolet, Jie Zhang, Carola Leuschner, Liangpeng Yang, Claudia S. Kettlun Leyton, Natalie Wall Fowlkes, Morgan Maureen Green, Lisa Hettrick, Dawei Chen, Fatemeh Masrorpour, Meidi Gu, Hadi Maazi, Alexey S. Revenko, Maria Angelica Cortez, James W. Welsh
Journal: Cancer Immunology Research
Cancer Immunol Res (2023) 11 (4): 486–500.
https://doi.org/10.1158/2326-6066.CIR-22-0547
Published: 03 April 2023
View article titled, Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti–PD-1 in Metastatic Non–Small Cell Lung Cancer
Open the PDF for Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti–PD-1 in Metastatic Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti–PD-1–Resistant Model of Non–Small Cell Lung Cancer

Dawei Chen, Hampartsoum B. Barsoumian, Liangpeng Yang, Ahmed I. Younes, Vivek Verma, Yun Hu, Hari Menon, Mark Wasley, Fatemeh Masropour, Sara Mosaffa, Tugce Ozgen, Katherine Klein, Maria Angelica Cortez, James W. Welsh
Journal: Cancer Immunology Research
Cancer Immunol Res (2020) 8 (7): 883–894.
https://doi.org/10.1158/2326-6066.CIR-19-0744
Published: 01 July 2020
View article titled, SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti–PD-1–Resistant Model of Non–Small Cell Lung Cancer
Open the PDF for SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti–PD-1–Resistant Model of Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses

James W. Welsh, Chad Tang, Patricia de Groot, Aung Naing, Kenneth R. Hess, John V. Heymach, Vassiliki A. Papadimitrakopoulou, Taylor R. Cushman, Vivek Subbiah, Joe Y. Chang, George R. Simon, Rishab Ramapriyan, Hampartsoum B. Barsoumian, Hari Menon, Maria Angelica Cortez, Erminia Massarelli, Quynh Nguyen, Padmanee Sharma, James P. Allison, Adi Diab, Vivek Verma, Uma Raju, Sherif G. Shaaban, Ramona Dadu, Maria E. Cabanillas, Kelvin Wang, Clark Anderson, Daniel R. Gomez, Stephen Hahn, Ritsuko Komaki, David S. Hong
Journal: Cancer Immunology Research
Cancer Immunol Res (2019) 7 (12): 1903–1909.
https://doi.org/10.1158/2326-6066.CIR-18-0793
Published: 02 December 2019
View article titled, Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses
Open the PDF for Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses in another window
Includes: Supplementary data